FI96919B - I vatten olösliga polypeptider - Google Patents

I vatten olösliga polypeptider Download PDF

Info

Publication number
FI96919B
FI96919B FI884297A FI884297A FI96919B FI 96919 B FI96919 B FI 96919B FI 884297 A FI884297 A FI 884297A FI 884297 A FI884297 A FI 884297A FI 96919 B FI96919 B FI 96919B
Authority
FI
Finland
Prior art keywords
water
salt
peptide
insoluble
pamoate
Prior art date
Application number
FI884297A
Other languages
English (en)
Finnish (fi)
Other versions
FI884297A0 (sv
FI96919C (sv
FI884297A (sv
Inventor
Piero Orsolini
Rolland-Yves Mauvernay
Romano Deghenghi
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of FI884297A0 publication Critical patent/FI884297A0/sv
Publication of FI884297A publication Critical patent/FI884297A/sv
Publication of FI96919B publication Critical patent/FI96919B/sv
Application granted granted Critical
Publication of FI96919C publication Critical patent/FI96919C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (7)

1. Förfarande för framställning av farmaceutiskt acceptabel komposition avsedd för fördröjd ooh styrd frigöring av ett läkemedel under en utsträckt tidsperiod, ooh att kompositio-nen innefattar en polylaktid, polyglykolid, en sampolymer av mjölksyra och glykolsyra, en blandning av sädana polymerer ooh en vattenlöslig peptid, kännetecknad av att, ett vat-tenolösligt peptidsalt dispergeras i en lösning av polylaktid, polyglykolid, en sampolymer av mjölksyra och glykolsyra eller en blanding av sädana polymerer, att lösningsmedlet torkas bort och att den resulterande blandningen formas till fasta partiklar, vilka är lämpliga för parenteral injicering eller subkutan implantation och att dä den placeras i en vattenhaltig omgivning av fysiologisk typ, frigör peptiden kontinuerligt under en period av ätminstone 1 vecka och med en initiell frigöring under de första 24 h som inte översti-ger 30% av den totalt frigjorda mängden. v 2. Förfarandet enligt krav 1, kännetecknad av att det farma- « « ceutiskt godtagbara saltet väljes ur gruppen pamoatsalt, • « · • · · ; f tannatsalt och stearatsalt.
3. Förfarandet enligt krav 1 eller 2, kännetecknad av att I I 1den vattenolösliga peptiden är ett farmaceutiskt godtagbart • · V.: sait av LHRH, eller en syntetiskt beredd analog därav.
4. Förfarandet enligt krav 3, kännetecknad av att den vat- • · · tenolösliga peptiden är pamoatsaltet av D-Trp6-LHRH. I! 96919 fin, en renininhibitor, ett tillväxthormon-frigörande hor-mon, peptid T eller syntetiska analoger och modifieringar därav.
6. Förfarandet enligt kraven 5, kannetecknad av att den vattenolösliga peptiden är pamoatsaltet av D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2.
7. Förfarandet enligt nägot av kraven 1-6, kännetecknad av att den har formen av injicerbara partiklar som har en storlek av 1-500 μιη. * · • · • · • · · • * * • t « ♦ • · · • IM « · » : : • · • · e · · • · · e ♦ * · « • · · ·· · • · « « · » • · « « « • · · « ♦ · • · • · * x : ·· · « · · ·« • · «· · • · • I I · ·
FI884297A 1987-09-21 1988-09-19 I vatten olösliga polypeptider FI96919C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8722134A GB2209937B (en) 1987-09-21 1987-09-21 Water insoluble polypeptides
GB8722134 1987-09-21

Publications (4)

Publication Number Publication Date
FI884297A0 FI884297A0 (sv) 1988-09-19
FI884297A FI884297A (sv) 1989-03-22
FI96919B true FI96919B (sv) 1996-06-14
FI96919C FI96919C (sv) 1996-09-25

Family

ID=10624108

Family Applications (1)

Application Number Title Priority Date Filing Date
FI884297A FI96919C (sv) 1987-09-21 1988-09-19 I vatten olösliga polypeptider

Country Status (23)

Country Link
US (2) US5192741A (sv)
JP (1) JPH0713023B2 (sv)
AT (1) AT397035B (sv)
AU (1) AU611944B2 (sv)
BE (1) BE1001685A5 (sv)
CA (1) CA1326438C (sv)
CH (1) CH675968A5 (sv)
DE (2) DE122004000023I2 (sv)
DK (1) DK175311B1 (sv)
ES (1) ES2009346A6 (sv)
FI (1) FI96919C (sv)
FR (1) FR2620621B1 (sv)
GB (1) GB2209937B (sv)
GR (1) GR1002244B (sv)
IE (1) IE60608B1 (sv)
IL (1) IL87790A (sv)
IT (1) IT1225148B (sv)
LU (1) LU87340A1 (sv)
NL (1) NL193818C (sv)
NO (2) NO178604C (sv)
PT (1) PT88557B (sv)
SE (1) SE503406C2 (sv)
ZA (1) ZA886827B (sv)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH681425A5 (sv) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (sv) * 1989-07-28 1992-01-15 Debiopharm Sa
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung
DE3935736A1 (de) * 1989-10-27 1991-05-02 Chemie Linz Deutschland Pressling mit retardierter wirkstofffreisetzung
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
JPH07507768A (ja) * 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
ES2151541T3 (es) * 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2178592C (en) * 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
PT754032E (pt) * 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5817627A (en) * 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE69735384T2 (de) 1996-12-20 2006-08-10 Alza Corp., Mountain View Gelzusammensetzungen und verfahren
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
CA2291659A1 (fr) * 1997-06-04 1998-12-10 Debio Recherche Pharmaceutique S.A. Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP1161257A2 (en) 1999-03-17 2001-12-12 Novartis AG Pharmaceutical compositions comprising tgf-beta
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6362308B1 (en) * 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
ATE409465T1 (de) 2000-10-06 2008-10-15 Pacira Pharmaceuticals Inc Parenteral verabreichbare mikropartikel- zubereitung mit kontrollierter freisetzung
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
SE518008C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
JP4748923B2 (ja) * 2000-12-27 2011-08-17 アレス トレーディング ソシエテ アノニム 低温微粉砕による脂質マイクロ粒子
US20070142325A1 (en) * 2001-01-08 2007-06-21 Gustavsson Nils O Starch
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7105181B2 (en) * 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
US20040043938A1 (en) * 2001-11-06 2004-03-04 Dinesh Purandare Combination therapy for estrogen-dependent disorders
SE0201599D0 (sv) * 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
US20060076295A1 (en) * 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
EP1622691B1 (en) 2003-03-14 2011-05-25 The Trustees of Columbia University in the City of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
CN101410174B (zh) * 2003-04-10 2011-04-06 Pr药品有限公司 一种用于生产基于乳化的微观粒子的方法
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
EP2444069B1 (en) 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
ATE511512T1 (de) * 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US8871712B2 (en) * 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
ES2400034T3 (es) 2005-01-14 2013-04-05 Camurus Ab Formulaciones bioadhesivas tópicas
CA2595385C (en) * 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
AU2006210627B2 (en) * 2005-02-01 2011-05-19 Attenuon, Llc Acid addition salts of Ac-PHSCN-NH2
CA2605000A1 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
WO2006125119A1 (en) 2005-05-17 2006-11-23 Sarcode Corporation Compositions and methods for treatment of eye disorders
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
AR055346A1 (es) * 2005-06-30 2007-08-22 Sod Conseils Rech Applic Composiciones farmaceuticas de glp -1
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
AU2007253702A1 (en) * 2006-05-22 2007-11-29 The Trustees Of Columbia University In The City Of New York Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
LT2164467T (lt) * 2007-06-06 2017-01-25 Debiopharm Research & Manufacturing Sa Lėto atpalaidavimo mikrodalelių farmacinė kompozicija
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
CA3105972A1 (en) 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
CA2714594A1 (en) * 2008-02-04 2009-08-13 Edward F. Leonard Fluid separation devices, systems and methods
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009277252B2 (en) 2008-07-30 2014-01-16 Mesynthes Limited Tissue scaffolds derived from forestomach extracellular matrix
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
ES2550308T3 (es) 2008-08-29 2015-11-06 Genzyme Corporation Formulaciones peptídicas de liberación controlada
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
EA022028B1 (ru) 2009-03-09 2015-10-30 Пронова Биофарма Норге Ас Композиции, содержащие масляную смесь жирных кислот и поверхностно-активное вещество, способы и применения композиций
CN102811705A (zh) * 2009-09-22 2012-12-05 赢创德固赛公司 具有不同生物活性剂负载构造的植入装置
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP2013515719A (ja) 2009-12-23 2013-05-09 デフィアンテ・ファルマセウティカ・ソシエダデ・アノニマ 循環器疾患の処置に有用な組み合わせ組成物
DK2398488T3 (en) * 2010-01-04 2019-01-28 Mapi Pharma Ltd DEPOT SYSTEM INCLUDING GLATIR FRAME ACETATE
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2383271B1 (es) 2010-03-24 2013-08-01 Lipotec S.A. Procedimiento de tratamiento de fibras y/o materiales textiles
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6092849B2 (ja) 2011-05-04 2017-03-08 バランス セラピューティックス, インコーポレイテッドBalance Therapeutics, Inc. ペンチレンテトラゾール誘導体
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
WO2013150384A1 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
BR112014028443B1 (pt) 2012-05-14 2021-01-19 Teijin Limited composição estéril esterilizada com radiação
WO2013174978A1 (en) 2012-05-25 2013-11-28 Camurus Ab Somatostatin receptor agonist formulations
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
FR3002735B1 (fr) * 2013-03-04 2015-07-03 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
AU2014331704A1 (en) 2013-10-10 2016-04-28 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2018523022A (ja) 2015-07-15 2018-08-16 インターナショナル アドヴァンスト リサーチ センター フォー パウダー メタラージー アンド ニュー マテリアルズ（エーアールシーアイ） 高効率性を備えたシリカエアロゲル断熱製品の改善された製造方法
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CA3077011A1 (en) 2017-09-26 2019-04-04 Nanomi B.V. Method for preparing micro-particles by double emulsion technique
CN110123658B (zh) * 2019-05-22 2022-07-15 上海璞萃生物科技有限公司 一种具有自组装聚集体结构的超分子多肽及其制备方法
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN116803378B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种格列齐特缓释片剂及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
CH660488A5 (en) * 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4632979A (en) * 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4647653A (en) * 1984-08-23 1987-03-03 Tulane Educational Fund Therapeutic peptides
ZA855567B (en) * 1984-08-31 1986-03-26 Salk Inst For Biological Studi Insulin-selective somatostatin analogs
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JPS61172813A (ja) * 1985-01-28 1986-08-04 Japan Atom Energy Res Inst ポリ乳酸を担体とする徐放性複合体の製造方法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5089471A (en) * 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
CA2012901A1 (en) * 1989-04-05 1990-10-05 Quirico Branca Amino acid derivatives

Also Published As

Publication number Publication date
GB8722134D0 (en) 1987-10-28
NO178604C (no) 1996-05-02
FR2620621B1 (fr) 1993-02-19
SE503406C2 (sv) 1996-06-10
DE3822459C2 (de) 1994-07-07
NO178604B (no) 1996-01-22
FI884297A0 (sv) 1988-09-19
DK518988D0 (da) 1988-09-16
CA1326438C (en) 1994-01-25
US5776885A (en) 1998-07-07
NL193818C (nl) 2000-12-04
SE8803321L (sv) 1989-03-22
BE1001685A5 (fr) 1990-02-06
LU87340A1 (fr) 1989-04-06
IL87790A0 (en) 1989-03-31
GB2209937B (en) 1991-07-03
PT88557B (pt) 1992-11-30
ES2009346A6 (es) 1989-09-16
GR1002244B (en) 1996-04-22
ZA886827B (en) 1989-05-30
US5192741A (en) 1993-03-09
IE60608B1 (en) 1994-07-27
JPH01121222A (ja) 1989-05-12
NO884154L (no) 1989-03-22
DE122004000023I2 (de) 2009-05-07
FR2620621A1 (fr) 1989-03-24
AT397035B (de) 1994-01-25
IT1225148B (it) 1990-11-02
NL193818B (nl) 2000-08-01
NO884154D0 (no) 1988-09-19
GB2209937A (en) 1989-06-01
NO2005012I2 (no) 2008-12-01
IL87790A (en) 1992-05-25
DK518988A (da) 1989-03-22
JPH0713023B2 (ja) 1995-02-15
SE8803321D0 (sv) 1988-09-20
DE3822459A1 (de) 1989-03-30
ATA223488A (de) 1993-06-15
IE882727L (en) 1989-03-21
AU2232688A (en) 1989-03-23
AU611944B2 (en) 1991-06-27
CH675968A5 (sv) 1990-11-30
IT8805213A0 (it) 1988-09-20
DK175311B1 (da) 2004-08-16
PT88557A (pt) 1988-10-01
GR880100619A (el) 1989-06-22
NL8802323A (nl) 1989-04-17
FI96919C (sv) 1996-09-25
FI884297A (sv) 1989-03-22

Similar Documents

Publication Publication Date Title
FI96919B (sv) I vatten olösliga polypeptider
US6399103B1 (en) Method of producing a sustained-release preparation
KR101231856B1 (ko) 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
AU767632B2 (en) Microencapsulation and sustained release of biologically active agent
AU670168B2 (en) Controlled release growth hormone containing microspheres
EP0462959B1 (en) Coated veterinary implants.
US5639480A (en) Sustained release formulations of water soluble peptides
US8637077B2 (en) Sustained-release preparation
IE902435A1 (en) Processes for the preparation of sustained release formulations of water soluble peptides
US5395916A (en) Biodegradable copolymer from hydroxy proline
JP2702729B2 (ja) 徐放性埋込剤
Anik et al. Delivery systems for LHRH and analogs
US5212154A (en) Preparation for treating complications in diabetes
NL195089C (nl) Preparaten van in water oplosbare peptiden met een langzame afgifte.
NERENBERG et al. ST ANIK, LM SANDERS, MD CHAPLIN, S. KUSHINSKY and

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: DEBIO RECHERCHE PHARMACEUTIQUE SA

FG Patent granted

Owner name: DEBIO RECHERCHE PHARMACEUTIQUE S.A.

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20050009

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L204

Extension date: 20130918

MA Patent expired